Product Description
Mechanisms of Action: THR-B Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Adrenoleukodystrophy
Phase 1: Cognition Disorders|Adrenoleukodystrophy|Adreno-myeloneuropathy
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CCALD | P2 |
Withdrawn |
Adrenoleukodystrophy |
2020-12-01 |
25% |
2019-03-21 |
Treatments |
| 2017-001684-21 | P1 |
Terminated |
Adrenoleukodystrophy |
2019-12-09 |
2022-03-13 |
Treatments |
|
| Sobetirome-CLIN-006 | P1 |
Withdrawn |
Adreno-myeloneuropathy|Adrenoleukodystrophy |
2013-09-01 |
2019-03-19 |
Treatments |
|
| Brain Uptake of GSK1034702 | P1 |
Completed |
Cognition Disorders |
2009-08-28 |
2019-03-18 |
Treatments |
|
| NCT00743405 | P1 |
Completed |
Cognition Disorders |
2008-12-15 |
2019-03-18 |
Treatments |